← All trials
NCT04410328
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 21, 2020
- Primary completion
- Dec 15, 2020
- Completion date
- Dec 15, 2021
- First posted
- Jun 1, 2020
- Last posted
- Jun 1, 2020
- Enrollment
- 132
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Rutgers UniversityLead sponsor
- Boehringer IngelheimCollaborator
- Rutgers UniversityOverall official - principal investigator
- Rutgers UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.